Literature DB >> 7568137

Sequence-specific inhibition of human immunodeficiency virus (HIV) reverse transcription by antisense oligonucleotides: comparative study in cell-free assays and in HIV-infected cells.

B Bordier1, M Perala-Heape, G Degols, B Lebleu, S Litvak, L Sarih-Cottin, C Hélène.   

Abstract

We have investigated two regions of the viral RNA of human immunodeficiency virus type 1 (HIV-1) as potential targets for antisense oligonucleotides. An oligodeoxynucleotide targeted to the U5 region of the viral genome was shown to block the elongation of cDNA synthesized by HIV-1 reverse transcriptase in vitro. This arrest of reverse transcription was independent of the presence of RNase H activity associated with the reverse transcriptase enzyme. A second oligodeoxynucleotide targeted to a site adjacent to the primer binding site inhibited reverse transcription in an RNase H-dependent manner. These two oligonucleotides were covalently linked to a poly(L-lysine) carrier and tested for their ability to inhibit HIV-1 infection in cell cultures. Both oligonucleotides inhibited virus production in a sequence- and dose-dependent manner. PCR analysis showed that they inhibited proviral DNA synthesis in infected cells. In contrast, an antisense oligonucleotide targeted to the tat sequence did not inhibit proviral DNA synthesis but inhibited viral production at a later step of virus development. These experiments show that antisense oligonucleotides targeted to two regions of HIV-1 viral RNA can inhibit the first step of viral infection--i.e., reverse transcription--and prevent the synthesis of proviral DNA in cell cultures.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7568137      PMCID: PMC40989          DOI: 10.1073/pnas.92.20.9383

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  13 in total

Review 1.  Specific regulation of gene expression by antisense, sense and antigene nucleic acids.

Authors:  C Hélène; J J Toulmé
Journal:  Biochim Biophys Acta       Date:  1990-06-21

2.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

3.  A retroviral RNA secondary structure required for efficient initiation of reverse transcription.

Authors:  D Cobrinik; L Soskey; J Leis
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

4.  Human immunodeficiency virus reverse transcriptase expressed in transformed yeast cells. Biochemical properties and interactions with bovine tRNALys.

Authors:  M L Sallafranque-Andreola; D Robert; P J Barr; M Fournier; S Litvak; L Sarih-Cottin; L Tarrago-Litvak
Journal:  Eur J Biochem       Date:  1989-09-15

5.  Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates.

Authors:  J Lisziewicz; D Sun; V Metelev; P Zamecnik; R C Gallo; S Agrawal
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

6.  Oligonucleotide-poly(L-lysine)-heparin complexes: potent sequence-specific inhibitors of HIV-1 infection.

Authors:  G Degols; C Devaux; B Lebleu
Journal:  Bioconjug Chem       Date:  1994 Jan-Feb       Impact factor: 4.774

7.  Mechanisms of the inhibition of reverse transcription by antisense oligonucleotides.

Authors:  C Boiziau; N T Thuong; J J Toulmé
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

8.  Antiviral activity of conjugates between poly(L-lysine) and synthetic oligodeoxyribonucleotides.

Authors:  J P Leonetti; B Rayner; M Lemaitre; C Gagnor; P G Milhaud; J L Imbach; B Lebleu
Journal:  Gene       Date:  1988-12-10       Impact factor: 3.688

9.  Poly(L-lysine)-conjugated oligonucleotides promote sequence-specific inhibition of acute HIV-1 infection.

Authors:  G Degols; J P Leonetti; M Benkirane; C Devaux; B Lebleu
Journal:  Antisense Res Dev       Date:  1992

10.  Functional sites in the 5' region of human immunodeficiency virus type 1 RNA form defined structural domains.

Authors:  F Baudin; R Marquet; C Isel; J L Darlix; B Ehresmann; C Ehresmann
Journal:  J Mol Biol       Date:  1993-01-20       Impact factor: 5.469

View more
  7 in total

1.  Human immunodeficiency virus type-1 reverse transcription can be inhibited in vitro by oligonucleotides that target both natural and synthetic tRNA primers.

Authors:  X Wei; M Götte; M A Wainberg
Journal:  Nucleic Acids Res       Date:  2000-08-15       Impact factor: 16.971

2.  A new peptide vector for efficient delivery of oligonucleotides into mammalian cells.

Authors:  M C Morris; P Vidal; L Chaloin; F Heitz; G Divita
Journal:  Nucleic Acids Res       Date:  1997-07-15       Impact factor: 16.971

3.  Mutations that confer resistance to template-analog inhibitors of human immunodeficiency virus (HIV) type 1 reverse transcriptase lead to severe defects in HIV replication.

Authors:  Timothy S Fisher; Pheroze Joshi; Vinayaka R Prasad
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  Phosphorothioate oligonucleotides derived from human immunodeficiency virus type 1 (HIV-1) primer tRNALys3 are strong inhibitors of HIV-1 reverse transcriptase and arrest viral replication in infected cells.

Authors:  R El Dirani-Diab; L Sarih-Cottin; B Delord; B Dumon; S Moreau; J J Toulme; H Fleury; S Litvak
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

5.  Engineering and Applications of DNA-Grafting Polymer Materials.

Authors:  Lu Peng; Cuichen Wu; Mingxu You; Da Han; Yan Chen; Ting Fu; Mao Ye; Weihong Tan
Journal:  Chem Sci       Date:  2013-05-01       Impact factor: 9.825

Review 6.  Nanotechnology and the treatment of HIV infection.

Authors:  Raveen Parboosing; Glenn E M Maguire; Patrick Govender; Hendrik G Kruger
Journal:  Viruses       Date:  2012-04-10       Impact factor: 5.048

7.  DNA-nanoparticle assemblies go organic: macroscopic polymeric materials with nanosized features.

Authors:  Elad D Mentovich; Konstantin Livanov; Deepak K Prusty; Mukules Sowwan; Shachar Richter
Journal:  J Nanobiotechnology       Date:  2012-05-30       Impact factor: 10.435

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.